Cant wait for the obvious big money to turn up on the data release for the 20 patients. That's when the fun really starts. I can see OSL being a 5 bagger by mid year. That will give it a market cap of 50% less than SRX but a player in their market and the Pancreatic market.
Also like CYP, that is another one of the bottom draw into early next year. Both have done most of the heavy lifting over the years to arrive at strong data points and commercialization. dyor
Ann: Progress Update on Global Pancreatic Cancer Clinical Study, page-7
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
0.025(2.30%) |
Mkt cap ! $20.89M | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.11 | $1.09 | $26.73K | 24.35K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6807 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.12 | 6617 | 1 |
View Market Depth
| Last trade - 16.10pm 07/08/2025 (20 minute delay) ? |
| OSL (ASX) Chart |